<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10408847</article-id><article-id pub-id-type="pmc">2362348</article-id><article-id pub-id-type="pii">6690372</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sigsgaard</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Herrstedt</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Andersen</surname><given-names>L J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Havsteen</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>S W</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kj&#x000e6;rb&#x000f8;l</surname><given-names>A-G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lund</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kj&#x000e6;r</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dombernowsky</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark</aff><aff id="aff2">Department of Oncology, Aalborg Hospital, Aalborg, Denmark</aff><aff id="aff3">Department of Oncology, Vejle Hospital, Denmark</aff><aff id="aff4">Department of Internal Medicine P, Bispebjerg Hospital, Denmark</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Department of Internal Medicine F, Gentofte Hospital, Niels Andersens Vej 65, 2900 Hellerup,Denmark</corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>1999</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>1999</year></pub-date><volume>80</volume><issue>3-4</issue><fpage>412</fpage><lpage>418</lpage><history><date date-type="received"><day>27</day><month>05</month><year>1998</year></date><date date-type="rev-recd"><day>20</day><month>10</month><year>1998</year></date><date date-type="accepted"><day>05</day><month>11</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D<sub>2</sub> antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223 women were enrolled and 218 patients (97.8&#x00025;) were evaluable for efficacy. Granisetron (<italic>n</italic> = 109) was superior to prednisolone plus metopimazine (<italic>n</italic> = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (<italic>P</italic> &#x0003c; 0.001) and prednisolone plus metopimazine was superior on days 2&#x02013;5 (<italic>P</italic> = 0.002). Overall, granisetron was superior on days 1&#x02013;5 (<italic>P</italic> = 0.009). The median number of cycles completed with granisetron was five (95&#x00025; confidence interval 4&#x02013;6) compared with two (95&#x00025; confidence interval 2&#x02013;2) for prednisolone plus metopimazine (<italic>P</italic> = 0.0019). Constipation and rash were reported more frequently with granisetron (<italic>P</italic> &#x0003c; 0.001 and <italic>P</italic> = 0.043 respectively) and palpitations more frequently with prednisolone plus metopimazine (<italic>P</italic> = 0.015). In conclusion, the number of cycles completed with granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both treatments declined during multiple cycles of moderately emetogenic chemotherapy. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>anti-emetics</kwd><kwd>dopamine D<sub>2</sub> antagonist</kwd><kwd>granisetron</kwd><kwd>metopimazine</kwd><kwd>multiple cycles</kwd><kwd>prednisolone</kwd></kwd-group></article-meta></front></article>